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Methods: Incident diagnoses of rheumatoid arthritis in persons over 18 years from 1995 to 2011
were identified from the UK Clinical Practice Research Datalink. There were 3876 cDMARD users
and were propensity score matched to 1938 nonusers, on a wide range of confounders. Impact on de-
mentia was assessed using survival models.
Results: cDMARD users were at reduced risk of dementia (hazard ratio: 0.60; 95% confidence in-
terval: 0.42–0.85). The effect was strongest in methotrexate users (hazard ratio: 0.52; 95% confidence
interval; 0.34–0.82).
Discussion: The strong effect of cDMARD use on halving of dementia risk requires replication in a
trial and may provide an important therapeutic pharmacological treatment.
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ease causing pain and inflammation in the joints [3], ulti-
mately leading to joint destruction and deformity. RA
affects between 0.5% and 1% of the general population
[4]. The economic impact is substantial with the total cost
of disease in the UK estimated to be between £3.8 and
£4.8 billion per year [2]. Classical disease-modifying anti-
rheumatic drugs (cDMARDs) have proven efficacy and
can control disease activity, reduce joint erosions [5], and
improve quality of life [6]. Current guidance recommends
a combination of cDMARDs (including methotrexate
[MTX] and at least one other cDMARD, plus short-term
glucocorticoids) as first line treatment, ideally within
3 months of symptom onset for people with recently
diagnosed active RA [2].
RA has been used as a model of negative consequences of
systemic inflammation such as cardiovascular disease, and
the cDMARDMTX is effective at reducing this [7]. In addi-
tion, other systemic inflammatory events not involving the
central nervous system are associated with an increased pro-
duction of the peripheral cytokine tumor necrosis factor-a,
increasing the risk of decline in AD [8].
For this reason, it seems reasonable to suggest that
cDMARDs, such as MTX, may prove beneficial for the
treatment of dementia where an inflammatory insult is
caused, such as protective effects have previously been
observed in patients exposed to arthritis or antiinflammatory
drugs [9].
The aim of this study is to describe the association of
cDMARD use on dementia development using data on a
large cohort of patients with incident RA from the UK Clin-
ical Practice Research Datalink (CPRD).2. Methods
2.1. Study design, setting, and source of data
We conducted a population-based retrospective cohort
study. Data were obtained from the UK CPRD [10]. The
CPRD comprises the entire computerized medical records
of a sample of patients attending general practitioners in
the UK, covering a population of 6.5 million patients from
433 contributing practices chosen to be representative of
the wider UK population. General practitioners in the UK
play a key role in the delivery of health care by providing pri-
mary care and referral to specialist hospital services. Patients
are registered with one practice that stores medical informa-
tion from primary care and hospital attendances. The CPRD
is administered by the Medicines and Healthcare products
Regulatory Agency of UK.
The CPRD records contain all clinical and referral events
in both primary and secondary care in addition to compre-
hensive demographic information, prescription data, and
hospital admissions. Data are stored using “Read Codes”
for diseases that are cross-referenced to the International
Classification of Diseases. Read Codes are used as thestandard clinical terminology system within UK primary
care. Only practices that pass quality control are used as
part of the CPRD database. Deleting or encoding
personal and clinic identifiers ensures the confidentiality of
information in the CPRD.
2.2. Participants
For the study population, the database was screened to
identify a first-ever clinical or referral record of RA occur-
ring from 1995 until the end of 2011, identified in CPRD
using a Read code, and occurring within the patients up-
to-standard registration period (Supplementary Table 1).
Patients had to have at least 1 year’s up-to-standard registra-
tion in CPRD before the index date. The validity of an RA
diagnosis in CPRD is high [11] for patients with specific
characteristics when using the American College of Rheu-
matology diagnostic criteria as the standard [12]. To ensure
the validity of the RA diagnosis, we used the same Read co-
des in the diagnostic groups used in the previous RA valida-
tion study [11], and patients were only included if they had
more than one medical code for RA on different dates. The
study population only included incident patients (those with
a first-ever record of RA at least 1 year after start of data
collection) who were aged 18 years or older at the date of
diagnosis. Using these criteria, we identified 11,772 patients
eligible for the present study.
2.3. Outcome and exposure
The outcome was incident dementia using standard UK
clinical terminology Read Codes (Supplementary Table 2).
This definition included AD, vascular dementia, and mixed
dementia. Patients were followed up to 15 years from the
date of RA diagnosis. The exposure was whether or not a pa-
tient had been prescribed a cDMARD after RA diagnosis.
cDMARDs selected for this study based on their frequency
within the data set were as follows: MTX, MTX sodium,
chloroquine phosphate/proguanil hydrochloride, ciclo-
sporin, cyclophosphamide, hydroxychloroquine sulphate,
sodium aurothiomalate, and sulfasalazine. For the purposes
of analysis, patients were categorized according to whether
or not they had been prescribed any cDMARD. As MTX
is among the most effective cDMARDs for patients with
RA with less toxicity and better tolerability, we further
categorized cDMARD use according to whether or not a
patient was prescribed MTX.
2.4. Potential confounders
Confounding variables included age, sex, body mass in-
dex (closest height, weight, and body mass index measure-
ments to the date of diagnosis), alcohol consumption,
smoking, calendar year of RA diagnosis, duration of RA
(time since first-ever record of RA), region of the UK,
comorbidities (tuberculosis, demyelinating disease,
cardiovascular disease, myocardial infarction, congestive
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disease, anemia, and osteoporosis), first presenting symp-
toms for early RA (joint pain, swollen tender joints, morning
stiffness, systemic malaise, weakness/loss of energy), medi-
cation use in the year before RA diagnosis (analgesics, hy-
pertensives, aspirin, cyclooxygenase-2 inhibitors, diabetic
medications, H2 blockers, nonsteroidal antiinflammatory
drugs [NSAIDS], proton pump inhibitors, statins, predniso-
lone, and other steroids), steroid use after RA diagnosis
(prednisolone and other steroids), whether or not the patient
has severe RA (systemic disease [extra-articular], seroposi-
tivity, erosive, multiple joint, or polyarthropathy) at the
time of diagnosis.2.5. Statistical methods
In randomized controlled trials, each person has an equal
probability of being in a treatment or control group. Obser-
vational study designs are limited by an inherent imbalance
of both known and unknown confounders making some pa-
tients more likely to receive cDMARDs than others. As
receipt of cDMARD was not randomly allocated in our
study, confounding by indication was accounted for by using
propensity score matching methods. Use of these methods
for the assessment of causality in epidemiological studies
has been previously described [13].
The propensity score represents the probability that a pa-
tient received the intervention (cDMARDs). In an RCT, the
propensity score is 50%, as each person has equal probabil-
ity of being in the treatment or control group. With a propen-
sity score, treated and control patients are matched
according to their probability of receiving treatment. For
example, a treated patient with a 75% chance of receiving
treatment is compared with a control with a 75% chance
of receiving treatment, and so on, across the full distribution
of probabilities.
To create a propensity score, a logistic regression model
is fitted where the outcome is cDMARD user (yes/no); and
the covariates listed previously are all included as potential
confounders. Based on the variables included in the model,
the propensity score is the predicted probability of a person
receiving outcome (cDMARD user or nonuser).
Having created a propensity score, and to address the
issue of confounding by indication, matching is used. Pa-
tients with contraindications to use of a drug may have
no comparable exposed subjects. A matched analysis will
exclude those cDMARD users with no comparable nonuser
controls [14]. Propensity scores are used to match each pa-
tient not receiving cDMARDs to two comparable
cDMARD users. Greedy matching is used, where a random
treated subject is selected and a nearest neighbor (untreated
subject) then selected for matching. Matched treated and
untreated subjects can only have propensity scores that
differ by at most a fixed, prespecified amount (the caliper
width). We chose a 0.02–standard deviation caliper
width [15].Immortal time bias is a common issue in epidemiological
studies, where the event of interest cannot occur for a certain
time span [16]. In the case of this proposed study, immortal
time bias would occur because of the definition of exposure,
where in the time from diagnosis of incident RA till receipt
of cDMARDs those in the “cDMARD user group” cannot
have the outcome by design, otherwise they would have
been classified as nonusers. To avoid the problem of
immortal time bias, we use time-varying exposures, where
in a survival analysis, the time period previous to the index
date of cDMARD treatment initiation (i.e., first prescription
of a cDMARD) is reclassified as nonuser for those in the
cDMARD user group.
Matched cDMARD users and their non-cDMARD user
controls were included in survival regression models to
describe the association between cDMARD use and time
to outcome. Consideration of competing risks is required,
where death is an important competing risk that precludes
development of dementia. A standard Cox regression sur-
vival model treats the competing risk of death as a censored
observation, but this assumes death is noninformative (e.g.,
that if they had not died, they would have the same chance
of developing dementia as their peers). To account for the
competing risk of death, we used the method of “Fine and
Gray”. This allows us to model the risk of dementia in those
who are currently event free and those who have previously
experienced a competing event (rather than only include
those in the risk set that have not died).
As we have a matched sample, this introduces a bias that
must be accounted for in the analysis stage. Matched sub-
jects will have correlation (greater similarity) in outcomes
than two randomly selected subjects. This is because their
baseline covariates are more similar, and baseline covariates
are related to outcomes.
We must therefore account for the lack of independence
in outcomes that have been induced by matching.
Hence, to account for the matched nature of the sample,
we use a robust variance estimator that accounts for the clus-
tering within matched sets [17]. The proportional hazards
assumption was assessed using Schoenfeld’s residuals, that
is, it was tested that the survival probability in exposed
and nonexposed patients was proportional over time.
Kaplan-Meier plots were used to estimate the probability
of dementia up to 15 years following RA diagnosis in
matched cDMARD users and nonusers.
Stata, version 13.1 (Stata, College Station, TX, USA),
was used for all statistical analyses.3. Results
Data were available for 11,772 patients with incident RA,
of whom 8312 (70.6%) became cDMARD users. They were
followed for a median (interquartile range) of 6.5 (3.4–9.9)
years (cDMARD users) and 5.1 (2.2–8.6) years (nonusers).
At the time of RA diagnosis, those who went on to become
cDMARD users were younger (mean age 58.3 years)
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proportion of patients were female (w70%) in both expo-
sure groups (Supplementary Table 1). cDMARD users
were more likely to drink and smoke, but less likely to
have comorbidities (particularly cardiovascular related co-
morbidities) and less likely to be taking medications (e.g.,
antihypertensive) and steroids (prednisolone) before RA
diagnosis. Over the study period, the percentage of patients
receiving cDMARDs increased over time—in 1995, only
63.5% of patients were cDMARD users, and this had
increased to over 80% of patients by 2009.
Propensity-score logistic regressionmodels achieved a C-
statistic (corresponding to the area under the receiver oper-
ating characteristic curve) of 0.71 for cDMARD users versus
nonusers, indicating moderate imbalance with respect to the
wide range of measured confounding factors before propen-
sity score matching was applied. Fig. 1 demonstrates how
the cDMARD user and nonuser groups have become
balanced on known and measured confounders after propen-
sity score matching—particularly in respect of age, comor-
bidities, and medication use. In the matched population,
there were 3876 cDMARD users and 1938 nonusers, and
only these patients are included in all subsequent analyses.
Of the cDMARD users, 2355 (60.8%) received MTX, and
1521 (39.2%) received other cDMARDs.
Dementia outcome was uncommon with 15-year rates of
2.0%. We observed a reduced risk of dementia in cDMARD
users versus nonusers, these being 0.5% versus 1.6% at 5
years and 1.5% versus 3.0% at 15 years. There was a strong
reduction in the risk of dementia for cDMARD users (hazard
ratio [HR]: 0.60; 95% confidence interval [CI]: 0.42–0.85),
with the effect being strongest in MTX users (HR: 0.52;
95% CI: 0.34–0.82) versus non-MTX users (HR: 0.70;
95% CI: 0.32–1.08).
Kaplan-Meier plots provide a visual assessment of the ef-
fect of cDMARD use on dementia incidence (Fig. 2) over the
duration of the 15-year follow-up. For dementia, a signifi-
cant difference is first observed at around 3 years of
follow-up, with lower risk of dementia in cDMARD users
with this difference remaining significant at over 10 years
of follow-up.4. Discussion
4.1. Main findings
Although dementia was uncommon, the large sample size
afforded by the study allowed us to identify a highly signif-
icant reduction in risk of dementia in cDMARD users versus
nonusers, these being 0.5% versus 1.6% at 5 years and 1.5%
versus 3.0% at 15 years. These percentages are concordant
with an estimated prevalence of 1.3% for the entire UK pop-
ulation in 2013 [1], bearing in mind that incidence is being
deferred to older ages. The observed associations of
cDMARD use with reduced dementia risk suggest this
may be a potential therapeutic option for patients withdementia, for whom no pharmacological drug treatments
are available or recommended, and would require further
exploration in future randomized controlled trials.4.2. What is already known
RA is an inflammatory disease that can also cause inflam-
mation in other parts of the body, including the heart, lungs,
and blood vessels [18]. In turn, dementia has biomarker
changes indicative of inflammatory insult [19]. Inflamma-
tion is a common characteristic of both RA and dementia,
and this fact is supported by common inflammatory bio-
markers that are being found in both diseases (e.g.,
interleukin-6 [20,21], interleukin-12 [22,23], C-reactive
protein [20,24], pentraxin 3 [25,26], endothelin-1 [27,28],
resistin [25,29], and receptors for advanced glycation end
products [25,30]). There is also an association between the
levels of cytokines important in the pathogenesis of RA,
such as tumor necrosis factor-a or interleukin-10, and pro-
gression of dementia [8,31,32]. The widespread reporting
of reductions in cardiovascular events associated with
MTX use, many initially seen in patients with RA, has
subsequently led to large-scale randomized controlled trials
in the general population to assess whether MTX can
improve outcomes after myocardial infarction [33].
The only medications currently licensed for the treatment
of dementia are acetylcholinesterase inhibitors and meman-
tine. However, the effect of other drugs in dementia has been
studied. Harmful results have been associated with aspirin
use and statin use among women [34], although statins
were initially reported as being protective in AD [9]. Protec-
tive effects of NSAIDs were reported in the 90s [9]. In addi-
tion, combined glucocorticoids and NSAID [35] or history
of NSAID use in epidemiological studies [36] suggested
decreased risk of dementia. Most recently, ibuprofen was
associated with better cognitive performance in a large UK
population cohort [37]. In our study, we controlled for
NSAID use, and hence, the protective effect of cDMARDs
observed is independent of NSAID use.
cDMARD therapy is effective at treating and controlling
RA and hence may prove beneficial for the treatment of
other inflammatory processes. AD, unambiguously a disor-
der with a considerable inflammatory component, might be
one such disorder. However, although the contribution of in-
flammatory processes to the neuropathology of AD is
considerable, suggesting a central nervous system target
for antiinflammatory therapies, other evidence increasingly
points to a peripheral inflammatory component to disease
[38]. Furthermore, critically for potential therapeutic strate-
gies, it is far from clear whether inflammation contributes to
disease processes or is to some degree protective. Multiple
observational studies are in line with the inflammation
element of AD being disease exacerbating, not least as
NSAIDs reduce the risk of AD in observational, real-world
studies [39]. The findings presented here suggest a relatively






Fig. 1. Baseline characteristics of patients, both in the whole cohort and in the propensity-score-matched (1 to 2) data sets: cDMARD user versus nonuser.
Abbreviations: BMI, body mass index; cDMARD, classical disease-modifying antirheumatic drugs; COX2, cyclooxygenase-2; NSAID, nonsteroidal antiin-
flammatory drug; PPI, proton pump inhibitors; RA, rheumatoid arthritis.
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Fig. 2. Kaplan-Meier plot of the effect of cDMARD use on dementia. Abbreviations: cDMARD, classical disease-modifying antirheumatic drugs; CI, confi-
dence interval.
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dence that inflammation exacerbates disease and antiinflam-
matory agents might have value as disease-modifying
agents. MTX, the cDMARD having the most effect, shows
relatively little penetrance of the blood-brain barrier, but
even a modest penetrance might have therapeutic benefit,
as suggested by its use for some brain tumors that are treated
with high doses of MTX [40]. Whether the lower dose as
used in clinical practice for RAwould be sufficient to cross
the blood-brain barrier to have a central effect in AD protec-
tion, or whether the strong protection observed in this study
suggests instead a peripheral action, raises a number of
important questions for further study. These primarily
include whether DMARDs cross the blood-brain barrier;
whether DMARDs affect central nervous system inflamma-
tion; and evidence of central nervous system inflammation in
RA. Although there is evidence suggesting the presence of
central nervous system inflammation in dementia, particu-
larly AD, there is a need for a valid and practical biomarker
to assess the role of antiinflammatory treatments.
In summary, the significant reduction in dementia risk in
cDMARD users observed in this study provides an important
potential therapeutic option worthy of consideration in
future randomized control trials.4.3. Strengths and limitations
One of the strengths of this study is the UK CPRD data on
which it is based with detailed date-stamped patient eventdata in primary and secondary care settings. The CPRD
practice network covers all of the United Kingdom, and
approximately 5% of all practices are covered by the
CPRD. People included in CPRD are broadly representative
of the UK population as a whole with respect to age, sex, so-
cioeconomic status, and UK region [41,42]. The high degree
of generalizability afforded by this very large sample
enables population-level inferences to be made, and the lon-
gitudinal nature of the data allowed us to explore association
of cDMARD use on dementia over a 15-year period of
follow-up.
A possible limitation of the study is the lack of validation
of individual cases of dementia in CPRD. Nevertheless, a
systematic review found a high positive predictive value re-
porting diagnosis of dementia 83.2 (95% CI: 74.1–90.1) us-
ing CPRD [43]. Coding of the diagnosis of RA is also
another potential limitation of the study. However, previous
studies have shown the validity of an RA diagnosis in CPRD
to be high [11]. A limitation is that it is not possible to study
biologic drug usage within CPRD (biologics are given by in-
jection or intravenously). Within this study, we only
included incident patients, UK National Guidelines recom-
mend cDMARDs as first-line therapy in early RAwith pro-
gression to a biologic for patients with inadequate response,
and a large proportion of patients do not need biologic ther-
apy in the first 2 years of disease [44]. The publication of the
National Institute for Health and Care Excellence technol-
ogy appraisal 36, in March 2002, provided guidance on the
use of etanercept and infliximab as recommended treatment
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two cDMARDs. It is possible that some of the patients in
our data set with severe RA are biologic users. However,
at the time of this CPRD datacut, only a minority of patients
with RA would have been receiving biological agents, and
60%–70% of these would have been taking MTX as well
as the biological agent. We tested for evidence of an interac-
tion between year of RA diagnosis (pre-and post-2002
before and after the introduction of biologics came into
widespread use) and cDMARD use on dementia outcome,
and the interaction was not significant (P5 .47); hence, bio-
logic use is unlikely to influence our findings.
Similar to others, we have used an intention-to-treat defi-
nition of cDMARD exposure, irrespective of adherence to
therapy [45]. To overcome the effect of confounding by indi-
cation, we used propensity score matching on known
measurable confounders, a strength of the study being the
comprehensive and detailed information on patient charac-
teristics, medication use, and comorbidities, particularly in
respect of traditional and disease-specific risk factors for car-
diovascular disease. Adjustment for length of follow-up and
year of RA diagnosis allowed us to control for changing
trends in both dementia and cDMARD use over time, in
addition to equalizing potential follow-up time in the expo-
sure groups. Furthermore, our modeling of mortality as a
competing event in analyses of time to dementia addressed
the issue of mortality precluding the experience of such
events, which otherwise would likely bias estimates of risk.
The results of the study are for the matched population,
which is a strength of the study as it minimizes bias due to
confounding by indication but limits the generalizability of
the findings. In addition, owing to the observational nature
of the study, there remains the potential for residual con-
founding that could attenuate or explain the observed asso-
ciations, due to unmeasured variables such as arthritis
disease severity, health, and lifestyle effects.4.4. What does this study add?
This study is the first to demonstrate a strong beneficial
effect of cDMARDs by suggesting a halving of risk of de-
mentia. This finding requires replication in other large obser-
vation studies and may provide an important therapeutic
pharmacological treatment for dementia to test in a future
randomized controlled trial.Acknowledgments
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1. Systematic review: The definition and context for
rheumatoid arthritis and dementia was searched in
the UK National Institute for Health and Care Excel-
lence guidelines. Literature was reviewed from
PubMed and the catalog of libraries of the University
of Oxford for meeting abstracts and presentations.
We hypothesized a potential impact of classical
disease-modifying antirheumatic drug (cDMARD)
use on dementia development in patients with rheu-
matoid arthritis because cDMARDs are widely used
to control this inflammatory disease and it is accepted
that dementia is an inflammatory disease too.
2. Interpretation: To support this potential effect, we
present a case definition for RA, dementia, and
cDMARDs together with robust analyses at a na-
tional level. Our findings demonstrate a strong bene-
ficial effect of cDMARD use on dementia.
3. Future directions: It will require further studies in ran-
domized clinical trials to validate cDMARDs as a
therapeutic pharmacological treatment for dementia.References
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